We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.51
Bid: 3.02
Ask: 4.00
Change: 0.00 (0.00%)
Spread: 0.98 (32.45%)
Open: 3.51
High: 0.00
Low: 0.00
Prev. Close: 3.51
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company / PDMR Shareholding

4 Jan 2017 16:36

RNS Number : 3690T
Proteome Sciences PLC
04 January 2017
 

Proteome Sciences plc

(the "Company")

Holdings in Company and PDMR Shareholding

 

Proteome Sciences plc (AIM:PRM) received notification from Vulpes Life Sciences Fund ("Vulpes"), of which Martin Diggle, a non-executive director of the Company, is a director and partner, that today, it purchased 105,590 ordinary shares of 1 pence each ("Ordinary Shares") at 5.5 pence per Ordinary Share (the "Transaction"). Following the Transaction, Vulpes (and Mr Diggle) have a beneficial interest in 53,943,715 Ordinary Shares, representing approximately 18.33% of the current issued share capital of the Company.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Vulpes Life Sciences Fund

2.

Reason for the Notification

a)

Position/status

Martin Diggle, non-executive director of the Company is a director and partner of Vulpes Life Sciences Fund

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Proteome Sciences plc

b)

LEI

n/a

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 1p each

Identification code

GB0003104196

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

04 January 2017

Price(s)

Volume(s)

5.5p

105,590

d)

Aggregated information:

· Aggregated volume

· Price

 

105,590 Ordinary Shares of 1 pence each purchased at an average price of 5.5 pence per Ordinary Share

e)

Date of the transaction

04 January 2017

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBLGDBSXGBGRS
Date   Source Headline
14th Jul 20117:00 amRNSCollaboration with Buck Institute - biomarket test
7th Jul 20117:00 amRNSCollaboration Agreement
29th Jun 20111:31 pmRNSAGM Statement
28th Jun 20118:12 amRNSDenamic ?6.9m EU Framework Grant
6th Jun 20111:21 pmRNSAnnual Financial Report
27th May 20117:00 amRNSFinal Results
27th May 20117:00 amRNSFinal Results
29th Mar 20117:00 amRNSTakeda Research Contract
28th Mar 20114:38 pmRNSBlocklisting Interim Review
8th Mar 20114:40 pmRNSSecond Price Monitoring Extn
8th Mar 20114:35 pmRNSPrice Monitoring Extension
31st Jan 20117:00 amRNSContract for Biomarker Services with Eisai
10th Jan 20113:39 pmRNSDirector/PDMR Shareholding
23rd Dec 20107:00 amRNSDirectorate Change
20th Dec 20107:00 amRNSResearch Contract
30th Nov 20107:00 amRNSTrading Statement
23rd Nov 201010:30 amRNSBlocklisting Interim Review
23rd Nov 20109:46 amRNSHolding(s) in Company
15th Nov 20107:00 amRNSProteome Sciences form alliance with ICON
14th Oct 20103:00 pmRNSHolding(s) in Company
30th Sep 20107:00 amRNSHalf Yearly Report
28th Sep 20107:00 amRNSStatement re Warranty Claim
23rd Sep 20107:00 amRNSCollaboration with Thermo Fisher
21st Jul 20104:26 pmRNSHolding(s) in Company
13th Jul 20107:00 amRNSProduct Launch
6th Jul 20101:11 pmRNSDirector/PDMR Shareholding
1st Jul 201011:10 amRNSHolding(s) in Company
30th Jun 20104:27 pmRNSResult of AGM,Loan Conversion,Total Voting Rights
28th Jun 20105:59 pmRNSCOMPLETION OF PLACING AND OVERSUBSCRIBED OPEN OFFE
18th Jun 20107:00 amRNSUpdate on warranty claim
17th Jun 20109:00 amRNSReport and Accounts
11th Jun 20107:00 amRNSPublication of Circular
8th Jun 201011:21 amRNSHolding(s) in Company
7th Jun 20104:40 pmRNSSecond Price Monitoring Extn
7th Jun 20104:35 pmRNSPrice Monitoring Extension
7th Jun 20104:22 pmRNSPreliminary Results
7th Jun 20104:17 pmRNSPlacing, Open Offer & Loan Conversion
2nd Jun 20107:00 amRNSReimbursement of lung cancer test in USA
26th Apr 201011:55 amRNSBlocklisting Interim Review
9th Apr 20107:00 amRNSLicense Agreement
11th Feb 20108:18 amRNSAlliance with Parexel
9th Feb 20107:00 amRNSChange of Adviser
1st Feb 20102:01 pmRNSHolding(s) in Company
23rd Dec 20093:55 pmRNSDirectorate Change
16th Nov 20091:39 pmRNSHolding(s) in Company
28th Oct 20097:00 amRNSRe Contract
26th Oct 20097:00 amRNSBlock Admission
23rd Oct 20094:40 pmRNSSecond Price Monitoring Extn
23rd Oct 20094:35 pmRNSPrice Monitoring Extension
30th Sep 20097:00 amRNSHalf Yearly Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.